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Coronary artery ligations to induce myocardial infarction (MI) in mice and rats are widely
used in preclinical investigation. However, myocardial ischemic damage and subsequent
infarct size are highly variable. The lack of standardization of the model impairs the
probability of effective translation to the clinic. Cardiac Troponin I (cTnI) is a major clinically
relevant biomarker.
Aim: In the present study, we investigated the prognostic value of cTnI for early
estimation of the infarct size.
Methods and Results: Infarcts of different sizes were induced in mice and rats by
ligation, at a random site, of the coronary artery. Kinetics of the plasma levels of cTnI
were measured. Heart function was evaluated by echocardiography, the percentage
of infarcted left ventricle and infarct expansion index were assessed from histological
section. We observed that plasma cTnI level peaked at 24 h in the infarcted rats and
between 24 and 48 h inmice. Sham operated animals had a level of cTnI below 15 ng/mL.
Infarct expansion index (EI) assessed 4 weeks after ligation showed a large variation
coefficient of 63 and 71% in rats and mice respectively. We showed a significative
correlation between cTnI level and the EI demonstrating its predictive value for myocardial
injury in small animal models.
Conclusion: we demonstrated the importance of cTnI plasma level as a major early
marker to assist in the optimal and efficient management of MI in laboratory animals
model. The presented results stress the need for comparable biomarkers in the animal
model and clinical trials for improved translation.
Keywords: myocardial infarction, troponin I, infarct size, prognostic value
INTRODUCTION
Heart disease remains a major cause of mortality worldwide. New treatment strategies
using gene and cell therapies have gained interest because their efficacy has now been
established in a preclinical setting. However, their translation into clinical practice has been
disappointing (Houser et al., 2012). Although numerous phase 1 clinical trials have demonstrated
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the safety and feasibility of new therapies that rely on the delivery
of cells to the myocardium, the efficacy of the treatments have
not been as convincing or effective as suggested in the preclinical
studies. The reasons for these shortcomings are multifactorial,
and general recommendations have been proposed to improve
translational research in heart failure (Patten and Hall-Porter,
2009). The scientific community believes that the optimization
of preclinical studies in small animal models is of utmost
importance for developing safe and effective therapies and
increasing the probability of effective translation to the clinic
(Houser et al., 2012).
Rat and mouse models of myocardial infarction (MI) are
widely recognized standard preclinical approaches used for the
assessment of new potential therapies (Patten and Hall-Porter,
2009). MI resulting from a coronary thrombosis is commonly
simulated by permanent coronary artery ligation in rodent and
murine models. These models have been continuously improved
since 1960, leading to a drastic reduction in post-operative
mortality. However, one of the principal limitations of these
models is the large variability in the infarct size (Degabriele
et al., 2004). The size of the infarct depends on the position of
the coronary ligature and coronary collateral circulation, which
varies from one individual to another (Toyota, 2005). It is
necessary to correctly evaluate the infarct size when assessing
remodeling or repair responses to a regenerative treatment
(Houser et al., 2012). The effectiveness of the model for a bias-
free evaluation of novel therapies requires an estimation of the
infarct size pre and post treatment.
Several techniques are currently available to gauge the
myocardial infarct size; however, they are imprecise (e.g.,
estimating the coronary ligature position and consequent
bleaching zone); demanding in terms of time, expertise,
and equipment (e.g., echocardiography or magnetic resonance
imaging); and only available for end-point evaluations (e.g.,
histological assessment of fibrosis). While quantification of
myocardial injury using biomarkers is common in clinical
settings, it is not used in preclinical investigations. Cardiac
troponins (cTn), particularly the I and T isoforms, are well-
established biomarkers for the diagnosis and prognosis of cardiac
injury and play a key role in the risk stratification of acute
coronary syndromes (Thygesen et al., 2010; Hallén, 2012; Hall
et al., 2015). The cardiac isoforms are highly specific and sensitive
for the evaluation of the extent of myocardial necrosis. In
addition, cTnI release from the injured myocardium can be
reliably detected early after the myocardial infarction.
The purpose of this study was to investigate the prognostic
value of cTnI for the quantification of MI size in small animal
models (rat and mouse) to improve the coronary artery ligation
experimental model.
MATERIALS AND METHODS
Animals
All animals received care in compliance with the European
Convention on Animal Care. The surgical procedures were
performed in accordance with the Swiss Animal Protection
Law after obtaining permission from the State Veterinary
Office, Fribourg and approval from the Swiss Federal Veterinary
Office, Switzerland (2013_51_FR and 2013_09_FR). All surgical
interventions were performed under isoflurane anesthesia. Effort
was made to diminish any animal suffering; specifically, all
animals received a subcutaneous injection of 0.1mg·kg−1
Temgesic (buprenorphine, 0.3mg·ml−1; ESSEX Chemie; Luzern,
Switzerland) after surgery.
Surgery
In total, 28 female Lewis rats (218 ± 9 g) and 23 NMRI female
mice (49± 5 g) (Janvier; Le Genest, France) were included in this
study.
As previously described (Frobert et al., 2014), the animals
were anesthetized with isoflurane and oxygen (5% for induction
and 2.5% for maintenance). The animals were placed on a
warming pad at 37◦C to avoid hypothermia during anesthesia
and ventilated with a 14-G IV cannula for the rats and 20-G
IV cannula for the mice (Abbocath, Abbott; Sligo, Ireland) at 80
cycles perminute (adapted to weight; Harvard Inspira Apparatus,
Inc.; Holliston, MA, USA). The hearts were accessed through a
left thoracotomy between the fourth and fifth interstitial space.
After opening the pericardium, a permanent ligation of the
left anterior descending coronary artery (LAD) was performed
(7/0 polypropylene suture, Ethicon, Inc.; Somerville, MA, USA).
Threemice and three rats were sham operated without a coronary
ligation. Three healthy mice and three healthy rats that did not
undergo surgery were also included as controls.
Blood Sampling and cTnI Assay
Blood was collected in Litium/Heparin tubes from the caudal
tail artery and jugular vein in the anesthetized rats and mice,
respectively, at various time points (2, 5, 24, 48, and 72 h)
after the LAD ligation. The blood was centrifuged, and the
plasma was immediately stored a −80◦C for up to 2 weeks.
Plasma was diluted 1/5 for rats and 1/7 for mice in AccuTNI3+
buffer (Beckman Coulter, Switzerland). cTnI was quantified
with the AccuTNI3+ immunoassay using a UniCel DxI 800
system (Beckman Coulter, Switzerland). The immunoassay
detects human cTnI with an analytical measuring range of 0.01–
80 ng/mL. The immunoassay also cross-reacts with mouse and
rat cTnI (Apple et al., 2008). The assays were performed initially
in triplicate for validation and then only once.
Echocardiography
Echocardiograms were recorded 2 and 6 weeks after LAD ligation
in a blinded manner by an experienced cardiologist as previously
described (Guex et al., 2014). Briefly, animals were anesthetized
with 2.5% isoflurane and placed in a left lateral position. Images
were recorded using a 15 MHz linear array transducer system
(Acuson, Sequoia C512, Siemens, Inc.; Malvern, PA, USA).
The fractional shortening (FS) and ejection fraction (EF) were
estimated based on the M-mode or a two-dimensional analysis,
respectively.
Histopathological Sampling and Analysis
The hearts were harvested, washed in KCl (1 M), and stored
at −20◦C for 1 h in an acrylic heart matrix (Harward apparatus).
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The hearts were cut with a razor blade into 2- or 1-mm sections
from the rats and mice, respectively: 6–8 sections were obtained
from the base to the apex. Each section was embedded in
paraffin using a standard histological procedure. The paraffin
blocks were sectioned at 5-µm intervals with a rotary microtome
and stained with Masson-Goldner trichrome staining. The slices
were successively incubated in Mayer’s Hematoxylin (Merck
AG; Zug, Switzerland), Acid Fuchsin-Ponceau (Sigma-Aldrich;
Buchs, Switzerland), Phosphomolybdic Acid Orange G (Merck
AG; Zug Switzerland and Sigma-Aldrich; Buchs, Switzerland),
and Lichtgrün (Sigma-Aldrich; Buchs, Switzerland) solutions.
The samples were dehydrated with an ascending ethanol series
and mounted with Eukitt (EM Sciences; Hatfield, PA, USA).
Images were acquired with a stereomicroscope Nikon SM2 800
mounted with a Nikon 1 camera (Nikon; Tokyo, Japan).
Bersoft Image Analysis software (Bersoft Technology and
Software; Lunenburg, Canada) was used to measure the scar
thickness in the middle of the infarct, septum thickness, left
ventricle (LV) cavity area, infarct area, and LV tissue area.
The infarct expansion index (EI) was calculated as ([LV cavity
area/whole LV area]/[infarct thickness/septum thickness]); the
whole LV area was measured as the combined LV cavity and
LV tissue area (Landa et al., 2008). The size of the infarct was
calculated as the percentage of the LV area (infarct area/LV tissue
area). The measurements were performed on one slice of each
heart section and averaged according to Takagawa et al. (2007).
Statistics
The results are presented as mean ± standard deviation. Linear
regression analyses were performed using Prism software. The
non-parametric Spearman test was computed in a two-tailed
manner. The non-parametric Wilcoxon matched pairs test was
used to compare two paired groups. Values were considered
significantly different when p < 0.05. Variability was estimated
using coefficients of variance (%CV).
RESULTS
Myocardial Infarction
A total of 28 rats and 23 mice were included in the study. The
MI group consisted of 22 rats and 16 mice that underwent a LAD
ligation. Peri-operative mortalities were low (no rat, one mice).
Each of the sham and healthy groups comprised three rats and
three mice.
The LAD ligations resulted in a reduction in heart function,
and there was a significant difference between the LAD-ligated
groups and the healthy and sham groups. The FS and EF are
presented in Figure 1. The ligations were performed at a random
site on the coronary artery. Accordingly, an assessment of the
heart function showed large variability on the echocardiogram
at the 2-week follow-up. For the mice, the EF ranged from 23–
59% (mean EF = 37 ± 11, CV = 29%). The sham-operated and
FIGURE 1 | Longitudinal echocardiographic assessments of heart function performed at 2 weeks (black bars) and 6 weeks (white bars) after the time
of surgery are represented for mice (above) and rats (below). The fractional shortening (FS) was calculated using the M-mode and ejection fraction (EF) from the
two-dimensional imaging mode. The animals were healthy (control group, n = 3 mice and rats), sham-operated (n = 3 mice and rats), or received a LAD ligation (n = 8
mice and n = 15 rats).
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FIGURE 2 | (A) Representative sections with Masson-Goldner trichome staining showing healthy myocardia in red and fibrotic tissues in green. Scale bars indicate
1.5mm for mice and 3mm for rats. The sections were from a healthy control and LAD ligated animal, respectively. (B) Myocardial injury was assessed as the
percentage of the infarcted area of the left ventricle and the infarct expansion index in mice and rats at 6 weeks post LAD ligation.
healthy animals had higher EF values that varied from 50–77%
(mean EF= 63± 14, CV= 21%) and from 66–77% (mean EF=
73± 6, CV= 8%), respectively.
At 2 weeks post-ligation, the minimum and maximum
EF values for the rats were 34% and 56%, respectively
(mean EF= 44± 6, CV= 13%). For the sham and healthy
groups, the minimum and maximum EF values were 64 and
70% (mean EF = 67 ± 3, CV = 5%) and 64 and 70%
(mean EF= 67± 3, CV= 4%), respectively.
After 6 weeks, the average EF and FS remained stable in
both the mice and rats in all of the groups compared with the
measurements performed at 2 weeks post-ligation. No significant
differences in FS and EF were observed between 2 and 6 weeks
post LAD ligation (Figure 1).
The Masson-Goldner trichrome stainings were performed
6 weeks after the LAD ligation to assess the infarct size and
expressed as a percentage of the LV and the EI. As illustrated in
Figure 2A, the histological measurements showed a wide panel
of myocardial injury, with large to small infarcts within the MI
group. The lesions increased from base to apex. The sham group
did not display any infarcts.
In ligated rats, the EI varied from of 0.025 to 0.276 and
revealed a wide range of myocardial infarct /CV of 63%;
Figure 2B). The dynamic range of the % of LV was low with
a minimum of 3.3% and a maximum of 21.7% (CV of 43%).
The dynamic range of EI was broader (CV of 63%). When
expressed as a percentage of the LV, the estimation of the
infarct size may be biased. Indeed, thinning of the LV wall
from remodeling-induced transmural infarct is not included in
the calculation. The EI showed higher accuracy for infarct size
variability estimation.
In mice, the dynamic ranges of EI and %LV were similar with
respective CV of 71 and 68%.
Kinetics of the Appearance of cTnI in the
Blood Plasma Following MI
The individual kinetics of the plasma concentration of murine
and rodent cTnI are represented in Figures 3A,B, respectively.
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FIGURE 3 | Representative individual kinetics of plasma cTnI for mice (A) and rats (B): cTnI levels were measured at 2, 5, 24, 48, and 72h post LAD
ligation (MI) or in sham-operated animals (sham). Y-axis scales have been individually optimized for each graph. The peak and the area under the plasma drug
concentration-time curve (AUC) are proportional to the myocardial damage, which are expressed as the expansion index (EI) and % of infarcted left ventricle (Inf). The
FS recorded 6 weeks post-MI is also reported.
The cTnI concentration peaked between 24 and 48 h in the
infarcted mice, and it varied between the individual animals. The
CV of the area under the curve (AUC) was 28%. For the sham
animals, the cTnI levels were either below the detection limit or
lower than 15 ng/mL.
Following LAD ligation, the plasma level of cTnI in the
rats peaked at 24 h for the large infarcts (Figure 3). An earlier
elevation of plasma cTnI was also observed in animals with the
lowest myocardial damage (EI < 0.07). The CV of the AUC
was 42%. The sham-operated animals had a level of cTnI below
3 ng/mL at 24 h.
Correlation Between cTnI and Infarct Size
The correlations between the level of cTnI and myocardial
injury measured 6 weeks after LAD ligation are presented in
Figure 4. For mice, we observed significant correlations between
the EI and plasma troponin levels at 24 and 48 h, mean value
between 24 and 48 h, and AUC. The highest r2 were obtained
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FIGURE 4 | Relationship between the expansion index (EI) and cTnI level: the EI was measured in all animals, including the healthy controls,
sham-operated, and infarcted animals, 6 weeks after surgery in the mice (A) and rats (B). The cTnI concentrations are presented at 24 and 48 h, as the mean
of the 24–48 h time period, and as the AUC. The r2 and p-values from the regression and correlation analyses are shown for each graph. The linear regression (black
line) and 95% confidence intervals (dotted lines) are represented.
between the EI and the mean 24–48 h value (r2 = 0.83, p <
0.001) or the cTnI AUC (r2 = 0.84, p < 0.001). For rats,
significant correlations were obtained between the EI and level
of cTnI measured at 24 h and the AUC, r2 of 0.79 and 0.85,
respectively.
Correlation Between cTnI and Heart
Function
The correlation between the cTnI levels and heart function,
represented by the FS and EF assessed at 2 and 6 weeks after
LAD ligation with echocardiography, were analyzed (Figure 5).
For mice, the selected value for the cTnI level was the mean of the
24 and 48 h plasma concentrations; the peak level at 24 h was used
for rats. As shown in Figure 5A, in mice, a significant correlation
was found between cTnI and heart function, with a maximum r2
of 0.56. In rats (Figure 5B), we observed a significant correlation
between the EF, FS, and cTnI level only at 2 weeks post LAD
ligation (maximum r2 was 0.66).
DISCUSSION
Monitoring troponin levels in the body is an important tool
for clinicians (Babuin and Jaffe, 2005; Thygesen et al., 2010).
However, the use of cardiac biomarkers in preclinical models
is almost only used in toxicology following administration of
cardiotoxic drugs (O’Brien et al., 2006; Engle et al., 2009;
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FIGURE 5 | The relationship between heart function (FS and EF) at 2 and 6 weeks after surgery and cTnI levels are represented as the mean value at
24–48h for mice (A) and the level at 24h for rats (B). The r2 and p-values from the regression and correlation analyses are shown for each graph. The linear
regression (black line) and 95% confidence intervals (dotted lines) are represented.
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Clements et al., 2010); it is rarely employed in LAD ligation MI
models (Borst et al., 2011; Gomes et al., 2013).
Discrepancies have been found between preclinical and
clinical studies of MI, which have emphasized the need for
improved small animal models. A key limitation of the LAD
ligation model is the intrinsic variability of MI size. Degabriele
et al. (2004) showed that the infarct size varied from 8–65%
depending on the ligature site. To assess the therapeutic efficacy
of a treatment, preclinical investigations often use MI size as
an end-point outcome without evaluating the infarct size before
treatment or using a biomarker-guided prediction of myocardial
injury. Therefore, the resulting high inter-animal variability
impairs the comparison between the treated and non-treated
groups and the accuracy of the therapeutic efficacy.
In this study, we demonstrated that the plasma level of
cTnI can be easily quantified in a sensitive manner in mice
and rats. We confirmed that a rapid rise in cTnI plasma levels
occurred following LAD ligation. Furthermore, we validated the
use of plasma cTnI as an early maker of myocardial injury
and, importantly, provided evidence of its predictive value for
myocardial injury in small animal models.
Numerous studies have validated the plasma level of cTnI
in animals using a model of cardiac toxicity induced by
isoproterenol (O’Brien et al., 2006; Apple et al., 2008; Schultze
et al., 2011). Indeed, it has been shown that commercially
available immunoassays for human cTn provide sensitive and
reproducible measurements of cTn levels in various laboratory
animals, including rats and mice (O’Brien et al., 2006).
Using the AccuTNI3+ Beckmann immunoassay, our findings
corroborate this previous study. When cTnI concentration
were measured on the same samples, the chemiluminescence-
based immunoassay, AccuTNI3+, showed a higher sensitivity
compared to commercially available mice specific ELISA
immunoassays (data not shown). Absolute values are specific to
the assay used. Nevertheless, the kinetics of cTnI appearance and
clearance were similar with all assays.
The detection of cTnI required either one measurement at
24 h for rats and two measurements at 24 and 48 h for mice,
making it appropriate for small animal models. Importantly,
we did not observe any cTnI in animals that received a sham
operation, suggesting that general muscle injury from surgery
does not interfere with cTnI detection.
We obtained a wide representation of infarct sizes by varying
the sites of ligation. The EI and percentage of infarcted LV varied
accordingly. In agreement with a study from Takagawa et al.
(2007), we observed that the EI is more accurate for evaluation
of the severity of myocardial damage than the percentage of
infarcted LV. Indeed, the EI calculation includes more measured
parameters, such as infarct thickness relative to septum thickness.
This parameter is critical for chronic models of MI that present
large inter-individual variability in remodeling and transmural
MI such as the rat LAD ligation model. By contrast, the mouse
model appeared less prone to inter-individual variability in
remodeling and wall thinning.
We found that the cTnI plasma levels were strongly correlated
with the EI when assessed at 2 and 6 weeks after LAD ligation.We
also discovered strong correlations between the EI and the peak
troponin I level and AUC values. cTnI levels with the highest r2
were selected as the optimal time point for blood sampling: 24 h
post LAD for rats and 24 and 48 h for mice (the mean value had
the highest correlation with the EI).
Previously, in acute MI, Vietta et al. (2013) reported that
the cTnI plasma concentration assessed 8 h after injury was
predictive of the myocardial damage found after 14 days in rats.
Additionally, the cTnT level assessed at 24 h after LAD ligation
has also been correlated with the size of the infarct in mice
(Metzler et al., 2002). In addition, the plasma concentration of
cTnI (measured 1 day post MI) as marker of infarct size has
been recently used in mice and validated by the classic 2-3-5-
triphenyltetrazolium-chloride assay performed 2 days post MI
(Santulli et al., 2015).
In contrast to acute MI, chronic MI may result in remodeling
of the LV. Indeed, to the best of our knowledge, this study
provides the first evidence that the cTnI level can predict the size
of a 6-week-old infarct in both mice and rats.
Taken together, our results indicate that the cTnI plasma level
can predict MI development within the first 24–48 h. The data
further suggest that the plasma level of cTnI can be used as
an early inclusion/exclusion criterion for selection in preclinical
experiments. This will improve group homogeneity, reducing
the number of animals needed, and further enhance the quality
of the experimental model. In addition, our results illustrate
that the systematic use of cTnI can provide valuable predictive
information for infarct size. One can envision a cardiac troponin-
guided approach for evaluation of regenerative therapies for
infarct size reduction.
cTnI is a widely recognized, highly specific and sensitive
biomarker for myocardial necrosis. Ingkanisorn et al. (2004)
demonstrated that the peak troponin I level correlated with the
infarct size measured by magnetic resonance imaging in patients
with ST-elevation MI. A recent large clinical study observed that
cTnI measured from 16 to 24 h following primary percutaneous
coronary intervention strongly correlated with the infarct size
and clinical outcomes throughout a 3-month follow-up after an
acute percutaneous intervention (Hall et al., 2015). Furthermore,
Hallén (2012) performed a review of clinical trials and found
that the coefficients of correlation between cTnI and infarct size
varied between 0.53 and 0.76 and that the correlation improved
with the development of more sensitive assays. Our results in
these animal models suggest that cardiac troponin could also be
employed as a surrogate test for infarct size prediction in trials
to monitor the patient’s response to treatment. Nevertheless,
a full time course of cTnI plasma level may not always be
available in patients and the time of the myocardial infarct
may not be always identified. In addition, further investigations
are necessary to define the mechanism of cTnI release, the
configuration of the protein in the plasma (native or degraded
protein or associated with other molecules) and its related
solubility.
Echocardiographic evaluation of cardiac function and
remodeling is often used as a selection criterion for MI. This
technique remains a reliable, readily available, affordable, non-
invasive assessment of cardiac function in small animals (Ram
et al., 2011). However, clinical equipment is most commonly
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used for echocardiography in small animal models. In the
present study, a longitudinal assessment of cardiac function
was performed with a transthoracic echocardiogram using a
clinical 15 MHz probe and performed by an expert cardiologist
to reduce inter-observer variability. Light anesthesia, heart rate,
and body temperature were maintained to ensure reliability
of the measurements. B-mode and M-mode imaging were
acquired at 2 and 6 weeks after LAD ligation, which allowed
assessments of the EF and FS. The decrease in heart function
we observed confirmed the development and progression
of MI in these animal models, in agreement with previous
reports (Patten and Hall-Porter, 2009). There were significant
correlations between the cTnI levels and heart function when
assessed 2 weeks post LAD ligation. Six weeks after the induced
infarction, significant correlations were observed formice but not
for rats.
Emerging high-resolution ultrasounds have been shown to
be a powerful tool for the evaluation of cardiac function
(Foster et al., 2011) and should greatly improve the accuracy
of global and regional cardiac function assessment, as well as
remodeling, in mice. Therefore, further investigations should be
undertaken to evaluate whether the weak r2 we observed may
be enhanced when better heart function measurements are made
using high-resolution ultrasound.
In conclusion, taken together, our results indicate that the
plasma cTnI level can predict infarct expansion better than
conventional echocardiographic assessments and suggest that
cTnI is a robust biomarker for MI development in small animal
models. This provides further prognostic information for cardiac
echocardiography. Using a prognostic biomarker such as TnI
also helps to define animal pre-selection for standardization of
the group and may lead to a more appropriate interpretation of
outcomes following experimental therapy. The use of biomarkers
will improve experimental investigations to assess the effects of
new therapeutics interventions.
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